Cetera Advisor Networks LLC Has $33.66 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Cetera Advisor Networks LLC lifted its stake in Eli Lilly and Company (NYSE:LLY) by 4.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 71,776 shares of the company’s stock after acquiring an additional 2,809 shares during the period. Cetera Advisor Networks LLC’s holdings in Eli Lilly and Company were worth $33,662,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of LLY. Wellington Management Group LLP grew its holdings in shares of Eli Lilly and Company by 1.6% during the 1st quarter. Wellington Management Group LLP now owns 20,324,267 shares of the company’s stock worth $6,979,760,000 after purchasing an additional 314,349 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich increased its holdings in Eli Lilly and Company by 533,336.4% in the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 19,059,681 shares of the company’s stock valued at $8,938,609,000 after buying an additional 19,056,108 shares during the period. Geode Capital Management LLC raised its stake in shares of Eli Lilly and Company by 1.1% in the 1st quarter. Geode Capital Management LLC now owns 14,867,424 shares of the company’s stock valued at $5,094,159,000 after buying an additional 159,964 shares in the last quarter. Morgan Stanley lifted its holdings in shares of Eli Lilly and Company by 44.1% during the 4th quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock worth $4,411,740,000 after acquiring an additional 3,691,436 shares during the period. Finally, Norges Bank acquired a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $3,416,206,000. Institutional investors own 81.38% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 600 shares of the company’s stock in a transaction on Monday, August 21st. The shares were sold at an average price of $546.51, for a total transaction of $327,906.00. Following the completion of the sale, the chief accounting officer now owns 5,378 shares in the company, valued at approximately $2,939,130.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CAO Donald A. Zakrowski sold 670 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $571.10, for a total transaction of $382,637.00. Following the transaction, the chief accounting officer now owns 4,708 shares of the company’s stock, valued at approximately $2,688,738.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Donald A. Zakrowski sold 600 shares of the business’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $546.51, for a total transaction of $327,906.00. Following the transaction, the chief accounting officer now owns 5,378 shares of the company’s stock, valued at approximately $2,939,130.78. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 536,138 shares of company stock valued at $20,881,627,358. 0.13% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on LLY shares. Wells Fargo & Company increased their price target on shares of Eli Lilly and Company from $615.00 to $650.00 and gave the stock an “overweight” rating in a research report on Monday, October 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $630.00 price target on shares of Eli Lilly and Company in a research note on Wednesday. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Eli Lilly and Company in a research report on Wednesday, November 8th. Jefferies Financial Group raised Eli Lilly and Company from a “hold” rating to a “buy” rating and lifted their price objective for the company from $408.00 to $615.00 in a report on Tuesday, August 8th. Finally, Citigroup upped their target price on shares of Eli Lilly and Company from $525.00 to $675.00 and gave the stock a “buy” rating in a report on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and twenty have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $557.00.

Eli Lilly and Company Stock Down 3.7 %

Shares of NYSE LLY opened at $588.41 on Thursday. Eli Lilly and Company has a 1 year low of $309.20 and a 1 year high of $629.97. The firm’s 50-day moving average is $577.56 and its 200-day moving average is $506.81. The company has a current ratio of 1.05, a quick ratio of 0.82 and a debt-to-equity ratio of 1.59. The firm has a market capitalization of $558.58 billion, a PE ratio of 106.60, a price-to-earnings-growth ratio of 3.72 and a beta of 0.33.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be issued a $1.13 dividend. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $4.52 annualized dividend and a yield of 0.77%. Eli Lilly and Company’s dividend payout ratio is currently 81.88%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.